Zevra therapeutics appoints experienced biopharma executive alvin shih, md, mba, to the board of directors

Celebration, fla., jan. 23, 2024 (globe newswire) -- zevra therapeutics, inc. (nasdaqgs: zvra) (zevra or the company), a rare disease therapeutics company, today announced the appointment of alvin shih, md, mba, to the company's board of directors (board) effective as of january 20, 2024. dr. shih has extensive experience in biotechnology leadership and rare disease therapeutics development and currently serves as president and ceo of catamaran bio, a biotechnology company developing cell therapies for multiple oncologic indications.
ZVRA Ratings Summary
ZVRA Quant Ranking